Table 3.
Case | Sex | Age | Primary site | Tumor size | Mitotic rate per 50HPF | MLN/TLN | Mutation | IM therapy | Outcome |
---|---|---|---|---|---|---|---|---|---|
1 | M | 60 | S | 8 | 23 | 2/4 | c-kit exon9 | Yes | Died of disease progression at 33 months after surgery |
2 | M | 58 | G | 5 | 12 | 1/2 | not available | No | DFS at 101 months after surgery |
3 | F | 59 | G | 5.5 | <5 | 4/4 | c-kit exon11 | Yes | DFS at 45 months after surgery |
4 | F | 70 | G | 9 | 8 | 1/9 | c-kit exon11 | Yes | DFS at 25 months after surgery |
5 | M | 31 | D | 18 | <5 | 2/2 | c-kit exon11 | Yes | Survival with residual disease at 3 months after surgery |
S = small intestine; G = stomach; D = duodenum MLN = metastatic lymph nodes; TLN = total examined lymph nodes; DFS = Disease-free survival.